Successful Management of Multi-Drug Resistant TB in Pregnancy: A Case Report
Asian Journal of Pregnancy and Childbirth,
Multi-drug resistant Tuberculosis (MDRTB) affects persons of all ages including women of child bearing age. The management of Multidrug resistant TB in pregnancy is controversial. However current guidelines for programmatic management of MDRTB include commencing pregnant women on treatment after the first trimester. Possible side effects of the drugs especially teratogenicity has been the major concern on whether or not to commence pregnant mothers.
We present a case of a 35 years old multi-gravida Nigerian woman who was managed for MDRTB during pregnancy. The patient was a previously drug sensitive TB patient who was treated for TB but lost to follow-up. At presentation pregnancy which was singleton was estimated at 19 weeks by Abdominal Ultra sound scan. Patient was treated with second line anti-Tb drugs and delivered at 38 weeks gestation; a healthy female baby with a birth weight of 2.5 kg.
Conclusions: Pregnant MDRTB patients can have successful outcomes if commenced on treatment after first trimester.
- multi-drug resistant TB
- second line drugs
How to Cite
World Health Organization. Global Tuberculosis Report; 2019.
Palacios R, Dallman M, Mu˜noz et al. “Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru,”. Clinical Infectious Diseases. 2009;48(10):1413–1419.
Department of Public health, National Tuberculosis and Leprosy Control Programme. National Tuberculosis, Leprosy and Buruli ulcer Management and control Guidelines 6th Edition. 2015:8–74.
Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532–49.
Mokhele I, Jinga N, Berhanu R. et al. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa. BMC Pregnancy Childbirth. 2021;21:453. Available:https://doi.org/10.1186/s12884-021-03956-6
Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: Retrospective-prospective cohort study from 2004 to 2007. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Healthcare Access - Regional Overviews 12 Communicable Disease Bulletin. 2013;18(40):pii=20601
Jagielski T, Brzostek A, van Belkum A, Dziadek J, Augustynowicz-Kopec E, Zwolska Z. A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland. European Journal of Clinical Microbiology & Infectious Diseases. 2015;34(1):41-53
Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC Infectious Diseases. 2017;17(1):655
Dudnyk, Andrii P Olena. Multidrug-resistant tuberculosis in pregnant women: Treatment and birth outcomes European Respiratory Journal. 2016;48
Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis. 2009;48(10):1413-1419.
Alaga A., Fairous MA, Razul MK. MDR TB Treatment of an Expectant Mother – A Case Report. J Lung Health Dis. 2020;4(1): 5-6
WHO consolidated guidelines on drug-resistant tuberculosis treatment; 2019.
Abstract View: 134 times
PDF Download: 38 times